Literature DB >> 28589505

Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction.

Tomohiro Fujisaka1, Shu-Ichi Fujita1, Daichi Maeda1, Kensaku Shibata1, Hideaki Takahashi1, Hideaki Morita1, Yoshihiro Takeda1, Takahide Ito1, Koichi Sohmiya1, Masaaki Hoshiga1, Nobukazu Ishizaka2.   

Abstract

Serum levels of the soluble urokinase-type plasminogen activator receptor (suPAR) reflect immune and inflammatory activation, and are shown to be associated with cardiovascular outcomes. We herein investigated the potential association between suPAR and left ventricular diastolic dysfunction among patients with preserved left ventricular ejection fraction (LVEF) and sinus rhythm. Among 291 patients who had sinus rhythm and an LVEF of ≥50% enrolled in the study, 26 (8.9%) were considered to have diastolic dysfunction. Patients with diastolic dysfunction had lower estimated glomerular filtration rate (eGFR), and higher systolic blood pressure (BPs), BNP, C-reactive protein, and suPAR than those without diastolic dysfunction. As compared with the first suPAR quartile, the fourth suPAR quartile was significantly associated with both diastolic dysfunction with an odds ratio of 8.95 [95% confidence interval (CI), 1.04-77.0, P < 0.05] after adjusting for sex, age, BPs log(eGFR), CRP, and diuretic use. On the other hand, receiver-operating characteristic curve (ROC) analysis showed that addition of log(suPAR) to the combination of age, sex, and log(eGFR), CRP, and diuretic use did not significantly improve the prediction of diastolic dysfunction. Among cardiac patients with preserved LVEF, serum suPAR was associated with diastolic dysfunction independent of confounding factors by logistic regression analysis. However, according to the ROC analysis, the utility of suPAR as a biomarker for diastolic dysfunction may be limited from a clinical point of view.

Entities:  

Keywords:  Diastolic dysfunction; Inflammatory biomarker; Soluble urokinase-type plasminogen activator receptor

Mesh:

Substances:

Year:  2017        PMID: 28589505     DOI: 10.1007/s00380-017-1002-7

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  47 in total

Review 1.  Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment.

Authors:  Mary Sandquist; Hector R Wong
Journal:  Expert Rev Clin Immunol       Date:  2014-08-21       Impact factor: 4.473

2.  Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.

Authors:  M Persson; G Engström; H Björkbacka; B Hedblad
Journal:  Atherosclerosis       Date:  2011-11-09       Impact factor: 5.162

Review 3.  The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation.

Authors:  Mario Del Rosso; Francesca Margheri; Simona Serratì; Anastasia Chillà; Anna Laurenzana; Gabriella Fibbi
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction.

Authors:  Junichi Matsubara; Seigo Sugiyama; Toshimitsu Nozaki; Koichi Sugamura; Masaaki Konishi; Keisuke Ohba; Yasushi Matsuzawa; Eiichi Akiyama; Eiichiro Yamamoto; Kenji Sakamoto; Yasuhiro Nagayoshi; Koichi Kaikita; Hitoshi Sumida; Shokei Kim-Mitsuyama; Hisao Ogawa
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

Review 5.  A Test in Context: E/A and E/e' to Assess Diastolic Dysfunction and LV Filling Pressure.

Authors:  Sumeet S Mitter; Sanjiv J Shah; James D Thomas
Journal:  J Am Coll Cardiol       Date:  2017-03-21       Impact factor: 24.094

6.  A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease.

Authors:  G Ndrepepa; S Cassese; S Braun; M Fusaro; L King; T Tada; A Schömig; A Kastrati; R Schmidt
Journal:  Nutr Metab Cardiovasc Dis       Date:  2013-10-04       Impact factor: 4.222

7.  Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).

Authors:  Benjamin Wallace Van Tassell; Ross Arena; Giuseppe Biondi-Zoccai; Justin McNair Canada; Claudia Oddi; Nayef Antar Abouzaki; Arehzo Jahangiri; Raquel Appa Falcao; Michael Christopher Kontos; Keyur Bharat Shah; Norbert Felix Voelkel; Charles Anthony Dinarello; Antonio Abbate
Journal:  Am J Cardiol       Date:  2013-10-04       Impact factor: 2.778

8.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

9.  Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction.

Authors:  Yusuke Okamoto; Shu-ichi Fujita; Hideaki Morita; Shun Kizawa; Takahide Ito; Kazushi Sakane; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  Heart Vessels       Date:  2014-09-16       Impact factor: 2.037

10.  Serum Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated with Low Left Ventricular Ejection Fraction and Elevated Plasma Brain-Type Natriuretic Peptide Level.

Authors:  Shu-Ichi Fujita; Suguru Tanaka; Daichi Maeda; Hideaki Morita; Tomohiro Fujisaka; Yoshihiro Takeda; Takahide Ito; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

View more
  3 in total

Review 1.  Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.

Authors:  Dimitrios Velissaris; Nicholas Zareifopoulos; Ioanna Koniari; Vasilios Karamouzos; Dimitris Bousis; Andreas Gerakaris; Christina Platanaki; Nicholas Kounis
Journal:  J Clin Med Res       Date:  2021-03-19

2.  Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients.

Authors:  Ahmad S Manshad; Fatima A Ballout; Jeffrey A Borgia; Jochen Reiser; Tochukwu M Okwuosa
Journal:  Front Cardiovasc Med       Date:  2022-01-28

3.  Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.

Authors:  Jan F Nauta; Yoran M Hummel; Jasper Tromp; Wouter Ouwerkerk; Peter van der Meer; Xuanyi Jin; Carolyn S P Lam; Jeroen J Bax; Marco Metra; Nilesh J Samani; Piotr Ponikowski; Kenneth Dickstein; Stefan D Anker; Chim C Lang; Leong L Ng; Faiez Zannad; Gerasimos S Filippatos; Dirk J van Veldhuisen; Joost P van Melle; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2019-11-11       Impact factor: 15.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.